95
Participants
Start Date
March 31, 2012
Primary Completion Date
January 31, 2014
Study Completion Date
January 31, 2014
CP-690,550
10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
CP-690, 550
5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
Fukuoka University Hospital, Fukuoka
Fukushima Medical University Hospital, Fukushima
JR Sapporo hospital, Sapporo
Kobe University Hospital, Chuo-ku, Kobe
Kanazawa Medical University Hospital, Kahoku-gun
National Hospital Organization Sagamihara National Hospital, Sagamihara
University of Miyazaki Hospital, Miyazaki
Nissay Hospital, Osaka
Jichi Medical University Hospital, Shimotsuke
Tokyo Teishin Hospital, Chiyoda-ku
Tokyo medical university Hachioji medical center, Hachiōji
Kanto Medical Center NTT East Corporation, Shinagawa-ku
Tokyo Medical University Hospital, Shinjyuku-ku
Tonami General Hospital, Tonami
Yamanashi Prefectural Central Hospital, Kofu
Jikei University Hospital, Tokyo
Lead Sponsor
Pfizer
INDUSTRY